Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment

Acromegaly is a rare disease most often caused by the prolonged secretion of excess growth hormone from a pituitary adenoma. The disease is associated with multiple significant comorbidities and increased mortality. The delay to diagnosis is often long. This may be because of low disease awareness among health care professionals, the insidious onset of differentiating features, and because patients are likely to present with complaints typical of other conditions more frequently seen in primary care. Early identification of acromegaly facilitates prompt treatment initiation and may minimize the permanent effects of excess growth hormone. The primary treatment for many patients will be pituitary surgery, although not all patients will be eligible for surgery or achieve a surgical cure. If biochemical control is not achieved following surgery, other treatment options include medical therapy and radiation therapy. Improved biochemical control may only alleviate rather than reverse the associated comorbidities. Thus, lifelong monitoring of patient health is needed, with particular attention to the management of cardiovascular risk factors. It is additionally important to consider the impact of both disease and treatment on patients’ quality of life and minimize that impact where possible, but particularly for chronic therapies. For the majority of patients, chronic therapy is likely to include somatostatin analog injections. In some circumstances, it may be possible to extend the dosing interval of the analog once good biochemical control is achieved. Additional convenience may be gained from the possibility of self-/partner administration of treatment or administration of treatment by a health care professional at home. Overall, it is clear that the care of patients with acromegaly requires a highly coordinated approach involving numerous specialties (eg, endocrinology, surgery, cardiology). Further, patients’ needs must be at the core of management and every effort must be made to improve health care experiences and minimize treatment burdens.

[1]  S. Ezzat,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  S. Melmed,et al.  Clinical, quality of life, and economic value of acromegaly disease control , 2011, Pituitary.

[3]  H. Shih,et al.  Radiation therapy in the management of pituitary adenomas. , 2011, The Journal of clinical endocrinology and metabolism.

[4]  P. Chanson,et al.  A consensus on criteria for cure of acromegaly. , 2010, The Journal of clinical endocrinology and metabolism.

[5]  P. Stewart,et al.  Mortality in patients with pituitary disease. , 2010, Endocrine reviews.

[6]  J. Romijn,et al.  Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. , 2010, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[7]  W. Ludlam Growth Hormone Deficiency after Treatment of Acromegaly: A Randomized, Placebo-Controlled Study of Growth Hormone Replacement , 2010 .

[8]  M. Molitch,et al.  Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly , 2009, Pituitary.

[9]  P. Chanson,et al.  Pituitary tumours: acromegaly. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[10]  J. Loeffler,et al.  Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[11]  P. Chanson,et al.  Guidelines for acromegaly management: an update. , 2009, The Journal of clinical endocrinology and metabolism.

[12]  P. Chanson,et al.  Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. , 2009, The Journal of clinical endocrinology and metabolism.

[13]  G. Arnaldi,et al.  Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly , 2009, Journal of endocrinological investigation.

[14]  H. Pfister,et al.  Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls. , 2009, European journal of endocrinology.

[15]  W. Drake,et al.  Successful use of weekly pegvisomant administration in patients with acromegaly. , 2008, European journal of endocrinology.

[16]  R. K. Hutson,et al.  Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. , 2009, Journal of endocrinological investigation.

[17]  X. Badia,et al.  Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. , 2009, The Journal of clinical endocrinology and metabolism.

[18]  M. Davi’,et al.  Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. , 2008, European journal of endocrinology.

[19]  R. Murray,et al.  A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. , 2008, The Journal of clinical endocrinology and metabolism.

[20]  T. Rokkas,et al.  Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. , 2008, World journal of gastroenterology.

[21]  Hang Lee,et al.  Changing patterns in diagnosis and therapy of acromegaly over two decades. , 2008, The Journal of clinical endocrinology and metabolism.

[22]  N. Pouratian,et al.  GAMMA KNIFE RADIOSURGERY FOR ACROMEGALY: OUTCOMES AFTER FAILED TRANSSPHENOIDAL SURGERY , 2008, Neurosurgery.

[23]  J. Petit,et al.  Proton stereotactic radiosurgery in management of persistent acromegaly. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[24]  P. Brown,et al.  Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. , 2007, Journal of neurosurgery.

[25]  P. Caron,et al.  Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa , 2007, Clinical endocrinology.

[26]  J. Wardlaw,et al.  A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly , 2007, Clinical endocrinology.

[27]  S. Melmed Medical progress: Acromegaly. , 2006, The New England journal of medicine.

[28]  Tien-Chun Chang,et al.  Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. , 2006, European journal of endocrinology.

[29]  L. Niskanen,et al.  Quality of life in treated patients with acromegaly. , 2006, The Journal of clinical endocrinology and metabolism.

[30]  X. Badia,et al.  Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. , 2006, European journal of endocrinology.

[31]  P. Caron,et al.  Effectiveness and tolerability of 3‐year lanreotide Autogel® treatment in patients with acromegaly , 2006, Clinical endocrinology.

[32]  X. Badia,et al.  Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. , 2005, The Journal of clinical endocrinology and metabolism.

[33]  J. Romijn,et al.  Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. , 2005, The Journal of clinical endocrinology and metabolism.

[34]  R. Fahlbusch,et al.  The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. , 2005, European journal of endocrinology.

[35]  I. Holdaway Treatment of Acromegaly , 2004, Hormone Research in Paediatrics.

[36]  S. Ezzat,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND TREATMENT OF ACROMEGALY , 2004 .

[37]  J. Bruce,et al.  Basal and Glucose-Suppressed GH Levels Less Than 1 μg/L in Newly Diagnosed Acromegaly , 2004, Pituitary.

[38]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[39]  S. Melmed,et al.  Pituitary tumor registry: a novel clinical resource. , 2000, The Journal of clinical endocrinology and metabolism.

[40]  M. Molitch Clinical manifestations of acromegaly. , 1992, Endocrinology and metabolism clinics of North America.

[41]  H. Quabbe [Treatment of acromegaly]. , 1982, Deutsche medizinische Wochenschrift.